Other languages Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Delayed Japan Exchange Other stock markets 02:00:00 2024-05-28 am EDT			5-day change	1st Jan Change
6,997 ^JPY	+1.10%		-2.06%	+2.93%

May. 14	Japan's Nikkei drifts sideways as more earnings, US CPI awaited	RE
May. 13	Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial	RE

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Japan's Nikkei drifts sideways as more earnings, US CPI awaited	May. 13
MÄRKTE ASIEN/Börsen wenig verändert - Mazda sehr schwach	May. 13
MÄRKTE ASIEN/Uneinheitlich - Anleger meiden Risiken vor US-Preisdaten	May. 13
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial	May. 13
Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	Apr. 30
Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024	Apr. 25
Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study of Fetroja®/F etcroja® (cefiderocol)	Apr. 18
Shionogi Completes Up to 75 Billion Yen Share Buyback	Mar. 29
GSK Unit ViiV Healthcare's Injectable HIV Treatment Shows 'Superior Efficacy' in Late-stage Trial	Mar. 07
Shionogi Buys Back Shares Worth Nearly 12 Billion Yen	Mar. 06
GSK says ViiV's cabotegravir study supports longer HIV dose interval	Mar. 05
GSK's ViiV Healthcare Says Four-month Interval Between Doses Possible for HIV Treatment Cabotegravir	Mar. 05
Shionogi & Co., Ltd. Announces Xocova Obtains Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection	Mar. 05
US urges court to preserve Obamacare mandate to cover cancer screenings, HIV drugs	Mar. 04
GSK's new HIV drug formula could support longer dosing intervals (March 4)	Mar. 04
GSK Says Data Show For First Time New Ultra Long-Acting Cabotegravir Formulation That Doubles Current Dosing Interval	Mar. 04
US court to weigh Obamacare mandate to cover HIV drug, cancer screenings	Mar. 04
PureTech notes positive results from Shionogi's EndeavorRx ADHD trial	Feb. 27
Akili, Inc. Announces Positive Results from Shionogi & Co., Ltd. Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx for Pediatric ADHD Patients in Japan	Feb. 27
Sector Update: Health Care Stocks Ease Late Afternoon	Feb. 26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Other languages

Filters